Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent

被引：0
|
作者：
M. Panisset
S. Gauthier
H. Moessler
M. Windisch
机构：
[1]  McGill Centre for Studies in Ageing,
[2] Montreal,undefined
[3] Canada,undefined
[4] EBEWE Arzneimittel GmbH,undefined
[5] Unterach,undefined
[6] and,undefined
[7] JSW Research,undefined
[8] Graz,undefined
[9] Austria,undefined
来源：
Journal of Neural Transmission | 2002年 / 109卷
关键词：
Keywords: Alzheimer's disease; Cerebrolysin; neurodegeneration; neurotrophic factors; peptide derivative.;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1089 / 1104
页数：15
相关论文
共 50 条
  • [41] A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease
    Ruether, E
    Husmann, R
    Kinzler, E
    Diabl, E
    Klingler, D
    Spatt, J
    Ritter, R
    Schmidt, R
    Taneri, Z
    Winterer, W
    Koper, D
    Kasper, S
    Rainer, M
    Moessler, H
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (05) : 253 - 263
  • [42] A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease
    Imbimbo, BP
    Troetel, WM
    Martelli, P
    Lucchelli, F
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2000, 11 (01) : 17 - 24
  • [43] A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease
    Templeton, L
    Barker, A
    Wesnes, K
    Wilkinson, D
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1999, 14 (04) : 239 - 245
  • [44] Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
    Henderson, Samuel T.
    Vogel, Janet L.
    Barr, Linda J.
    Garvin, Fiona
    Jones, Julie J.
    Costantini, Lauren C.
    NUTRITION & METABOLISM, 2009, 6
  • [45] Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
    Samuel T Henderson
    Janet L Vogel
    Linda J Barr
    Fiona Garvin
    Julie J Jones
    Lauren C Costantini
    Nutrition & Metabolism, 6
  • [46] Applicability of Press Needles to a Double-blind Trial A Randomized, Double-blind, Placebo-controlled Trial
    Miyazaki, Shougo
    Hagihara, Akihito
    Kanda, Ryo
    Mukaino, Yoshito
    Nobutomo, Koichi
    CLINICAL JOURNAL OF PAIN, 2009, 25 (05): : 438 - 444
  • [47] Effects of Cerebrolysin on neuropsychiatric symptoms in Alzheimer's disease: results of a randomized, placebo-controlled trial
    Alvarez, A.
    Cacabelos, R.
    Couceiro, V.
    Aleixandre, M.
    Doppler, E.
    Novak, P.
    Moessler, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 72 - 72
  • [48] Repetitive transcranial magnetic stimulation as a treatment for Alzheimer's disease: A randomized placebo-controlled double-blind clinical trial
    Moussavi, Zahra
    Uehara, Maria
    Rutherford, Grant
    Lithgow, Brian
    Millikin, Colleen
    Wang, Xikui
    Saha, Chandan
    Mansouri, Behzad
    Omelan, Craig
    Fellows, Lesley
    Fitzgerald, Paul B.
    Koski, Lisa
    NEUROTHERAPEUTICS, 2024, 21 (03)
  • [49] The effects of fenugreek seed extract supplementation in patients with Alzheimer's disease: A randomized, double-blind, placebo-controlled trial
    Foroumandi, Elaheh
    Javan, Roghayeh
    Moayed, Leili
    Fahimi, Hossein
    Kheirabadi, Fereshteh
    Neamatshahi, Mahboubeh
    Shogofteh, Fazeleh
    Zarghi, Azam
    PHYTOTHERAPY RESEARCH, 2023, 37 (01) : 285 - 294
  • [50] Cannabidiol for behavior symptoms in Alzheimer's disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial
    Velayudhan, Latha
    Dugonjic, Marta
    Pisani, Sara
    Harborow, Lucy
    Aarsland, Dag
    Bassett, Paul
    Bhattacharyya, Sagnik
    INTERNATIONAL PSYCHOGERIATRICS, 2024, 36 (12) : 1270 - 1272
12345